Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Hypertension. 2024 Jan 4;81(3):604–613. doi: 10.1161/HYPERTENSIONAHA.123.21910

Table 2.

Comparison of AVS, cross-sectional imaging, and aldosterone driver mutations of study participants, stratified by post-operative biochemical outcomes.

PA cure (220) Partial improvement (34) No improvement (29) p value
AVS Lateralization a
LL 161 (73,2%) 15 (46.9%) 7 (33.3%) <0.0001
LB 11 (5.0%) 9 (28.1%) 11 (52.4%)
BL 36 (16.4%) 4 (12.5%) 3 (14.4%)
FL 12 (5.5%) 4 (12.5%) 0 (0 %)
CT findings b
Ipsilateral nodule 165 (79.7%) 20 (58.8%) 11 (37.9%) <0.0001
Contralateral nodule 7 (3.4%) 1 (2.9%) 3 (10.3%)
Bilateral 9 (4.3%) 2 (5.9%) 6 (20.7%)
No nodule 26 (12.6%) 11 (32.4%) 9 (31.0%)
Aldosterone-driver mutation c
CACNA1D 41 (33.1%) 10 (58.8%) 9 (69.2%) 0.0035
KCNJ5 52 (41.9%) 5 (29.4%) 3 (23.1%)
ATPase 31 (25.0%) 2 (11.8%) 1 (7.7%)
a

AVS results were classified as lateralized (L) or bilateral (B) based on lateralization indices ≥4 or <4, respectively. Baseline (first letter) and cosyntropin-stimulated (second letter) AVS results are shown. F stands for failed adrenal vein cannulation. Patients from Munich University (7) had AVS only without cosyntropin stimulation, and patients from University of Pennsylvania (3) had AVS only without cosyntropin stimulation, and they were not included in this table.

b

Cross-sectional imaging data was not available in 13 patients with PA cure.

c

In cases with multiple CYP11B2-positive areas, DNA sequencing was performed on the dominant lesions.